Table 2.

Patient Characteristics, by Study Component

	Phase I	Phase II
	Sorafenib + Bevacizumab	Sorafenib + Bevacizumab	Sorafenib	Total
Age
Median (Range in years)	66 (18–79)	59 (54–80)	55 (52–61)	57 (52–80)
Gender
Female	3 (17.6%)	1 (25.0%)	1 (33.3%)	2 (28.6%)
Male	14 (82.4%)	3 (75.0%)	2 (66.7%)	5 (71.4%)
Race
White	13 (76.5%)	4 (100.0%)	3 (100.0%)	7 (100.0%)
Black	2 (11.8%)
Asian	2 (11.8%)
ECOG Performance Score
0		3 (75.0%)	2 (66.7%)	5 (71.4%)
1		1 (25.0%)	1 (33.3%)	2 (28.6%)
History of Cirrhosis
Yes	7 (41.2%)	2 (50.0%)	2 (66.7%)	4 (57.1%)
No	10 (58.8%)	2 (50.0%)	1 (33.3%)	3 (42.9%)
Current Disease Status
Intrahepatic	8 (47.1%)	2 (50.0%)	2 (66.7%)	4 (57.1%)
Extrahepatic	9 (52.9%)	2 (50.0%)	1 (33.3%)	3 (42.9%)
Vascular Invasion
Yes	3 (20.0%)
No	12 (80.0%)	4 (100.0%)	3 (100.0%)	7 (100.0%)
Missing	2
Differentiation
Well	2 (11.8%)
Moderate	11 (64.7%)	3 (75.0%)	2 (66.7%)	5 (71.4%)
Poor	3 (17.6%)	1 (25.0%)	1 (33.3%)	2 (28.6%)
Undifferentiated, anaplastic	1 (5.9%)
Tumor Status
Recurrent		1 (25.0%)		1 (14.3%)
Unresected	17 (100.0%)	3 (75.0%)	3 (100.0%)	6 (85.7%)